Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study

Authors:
Publisher website
Google Scholar
Abstract
No abstract available
Funding Information
  • Takeda Pharmaceuticals U.S.A.
  • Janssen Pharmaceutica
  • National Institutes of Health (K23KD111995-01A1)
  • Crohn's and Colitis Foundation
  • National Institute of Diabetes and Digestive and Kidney Diseases (K23DK117058, R03DK129631)

This publication has 20 references indexed in Scilit: